Wockhardt names new director, reports mixed results and US exit

Wockhardt Limited reported its unaudited financial results for the quarter and half year ended September 30, 2025. Standalone net profit after tax was ₹54 crore for the quarter and ₹123 crore for the half year. Total standalone income for the quarter was ₹410 crore and ₹848 crore for the half year. Consolidated results show a net profit after tax of ₹82 crore for the quarter but a loss of ₹26 crore for the half year. Total consolidated income for the quarter was ₹803 crore and ₹1,561 crore for the half year.

The company's board of directors, at its meeting on November 3, 2025, approved the appointment of Mr. Om Prakash Bhatt as an additional non-executive independent director, effective immediately. Mr. Bhatt, a seasoned leader with extensive experience including as chairman and CEO of State Bank of India, will serve until shareholder approval is obtained and subsequently for a five-year term until November 2, 2030.

Wockhardt also disclosed a decision to exit its US generic pharmaceutical business, leading to a voluntary liquidation filing for its US step-down subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC, effective July 11, 2025. This deconsolidation resulted in an impact of ₹97 crore, recorded as an exceptional item.